Skip to content

Study · Not a test of the peptide alone · 2014

1 result

Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the AMPK pathway.

Xu WW, Guan MP, Zheng ZJ, Gao F, Zeng YM, Qin Y, Xue YM

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology11 Feb 2014Cited by 35 (Europe PMC)

PMID24556697 (opens in a new tab)DOI10.1159/000358623 (opens in a new tab)PepBankPUB-24556697
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking AICAR (acadesine).

  1. 01LabNot a test of AICAR (acadesine) aloneIn vitro (cells)Mechanism

    In rat mesangial cells, AICAR induced the AMPK pathway activation associated with exendin-4.

    In plain wordsIn cells from rats, AICAR induced AMPK pathway activation associated with exendin-4.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseAMPK pathway activation
    Study

    ratn: not reported in source

    high-glucose-treated mesangial cells
    Outcome group
    Receptor activity and mechanism · Kidney and urinary

    Source sentences

    Summary
    Moreover, the activation of the AMPK pathway by exendin-4 was induced by AICAR, which was inhibited by compound C.
    2 context sentences
    Summary · context
    Rat mesangial cells (MCs) were treated with exendin-4 under high glucose conditions.
    Summary · context
    AMP-activated protein kinase (AMPK) inhibitors (compound C) and agonists (AICAR) were used to analyze the role of this kinase.

    In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking AICAR (acadesine).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02690883

Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy

Nanfang Hospital, Southern Medical Universityn = 928 Apr 2016 to 30 Dec 2019

Diabetic Nephropathies

Trial pageClinicalTrials.govUpdated 9 Mar 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    21 Oct 2026, 15:58 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.